Table 1. Clinical Characteristics of... | American Society of Hematology

Table 1.

Clinical Characteristics of B-Cell CLL Patients

Patient No.	Diagnosis	Modified Rai Stage	Previous Treatment	Active Disease^*	Fludarabine Refractory
1	CLL	IR	None	Yes	NA
2	CLL	IR	None	No	NA
3	CLL	IR	None	No	NA
4	CLL	IR	None	Yes	NA
5	CLL	HR	C + P, Flu, CHOP	Yes	Yes
6	CLL	IR	None	No	NA
7	CLL	HR	C + P, 9AC	Yes	NA
8	CLL	IR	None	Yes	NA
9	CLL	HR	C + P, Flu, 2CDA	Yes	Yes
10	CLL	IR	None	Yes	NA

Patient No.	Diagnosis	Modified Rai Stage	Previous Treatment	Active Disease^*	Fludarabine Refractory
1	CLL	IR	None	Yes	NA
2	CLL	IR	None	No	NA
3	CLL	IR	None	No	NA
4	CLL	IR	None	Yes	NA
5	CLL	HR	C + P, Flu, CHOP	Yes	Yes
6	CLL	IR	None	No	NA
7	CLL	HR	C + P, 9AC	Yes	NA
8	CLL	IR	None	Yes	NA
9	CLL	HR	C + P, Flu, 2CDA	Yes	Yes
10	CLL	IR	None	Yes	NA

Abbreviations: IR, intermediate risk; HR, high risk; C, chlorambucil; P, prednisone; Flu, fludarabine; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; 9AC, 9-aminocamptothecin; 2CDA, cladribine; NA, not applicable.

Active disease defined as required treatment within 2 months of donating cells.

View Large

This Feature Is Available To Subscribers Only